MRI影像组学模型鉴别HER2零表达、低表达与阳性乳腺癌的构建与验证
回顾性纳入592例病理确诊乳腺癌患者,基于多参数MRI提取影像组学特征构建两个模型,分别鉴别HER2零表达与低表达或阳性(任务1)以及HER2低表达与阳性(任务2)。任务1外部验证集AUC 0.78但特异度为0.0%,任务2三个数据集AUC 0.75~0.77,联合病理特征的列线图AUC为0.80~0.87。
要点
- 任务1模型在外部验证集敏感度100.0%但特异度0.0%,需警惕假阳性。
- 任务2影像组学模型三组AUC 0.75~0.77,联合病理特征列线图AUC升至0.80~0.87。
- 任务1未构建列线图,因无临床病理或常规MRI特征独立于影像组学标签与HER2状态相关。
核心结论
- MRI影像组学特征可用于鉴别HER2零表达与HER2低表达或阳性乳腺癌,以及鉴别HER2低表达与HER2阳性乳腺癌。
- MRI影像组学可能有助于筛选适合新型或传统HER2靶向治疗的患者,尤其是免疫组化结果不明确或难以进行荧光原位杂交检测的患者。
研究设计与样本
- 回顾性研究,纳入592例病理确诊乳腺癌患者(平均年龄47.0±18.0岁),来自某医疗系统两家医院,2016年4月至2022年6月行乳腺MRI。
- HER2状态采用三分类系统经病理确定;放射科医师评估肿瘤常规MRI特征并在多参数序列(T2WI、DWI、ADC图、T1WI延迟增强)上手动分割肿瘤提取影像组学特征。
- 采用最小绝对收缩和选择算子分析构建两个影像组学标签:任务1鉴别HER2零表达与HER2低表达或阳性,任务2鉴别HER2低表达与HER2阳性。
- 医院1患者随机分为发现集(任务1 n=376;任务2 n=335)和内部验证集(任务1 n=161;任务2 n=143);医院2患者构成外部验证集(任务1 n=55;任务2 n=50)。
- 采用多变量逻辑回归分析构建列线图,联合影像组学标签与临床病理及常规MRI特征。
关键影像表现/征象
- 原文未报告具体影像征象,仅描述基于T2WI、DWI、ADC图和T1WI延迟增强序列提取影像组学特征。
诊断标准与关键数值
- 任务1影像组学模型在发现集、内部验证集、外部验证集的AUC分别为0.89、0.86、0.78,敏感度分别为99.4%、98.6%、100.0%,特异度分别为69.0%、76.5%、0.0%。
- 任务2影像组学模型在发现集、内部验证集、外部验证集的AUC分别为0.77、0.75、0.77,敏感度分别为93.8%、92.9%、97.0%,特异度分别为32.3%、6.8%、29.4%。
- 任务2列线图纳入MRI影像组学标签及三个与HER2低表达独立相关的病理特征(组织学分级III、高Ki-67指数、孕激素受体阳性),在发现集、内部验证集、外部验证集的AUC分别为0.87、0.83、0.80。
- 任务1未构建列线图,因无临床病理或常规MRI特征独立于MRI影像组学标签与HER2状态相关。
临床应用与阅片要点
- 原文未据此给出具体阅片或报告建议。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Breast cancer HER2 expression has been redefined using a three-tiered system, with HER2-zero cancers considered ineligible for HER2-targeted therapy, HER2-low cancers considered candidates for novel HER2-targeted drugs, and HER2-positive cancers treated with traditional HER2-targeted medications. OBJECTIVE. The purpose of this study was to assess MRI radiomics models for a three-tiered classification of HER2 expression of breast cancer. METHODS. This retrospective study included 592 patients with pathologically confirmed breast cancer (mean age, 47.0 ± 18.0 [SD] years) who underwent breast MRI at either of a health system's two hospitals from April 2016 through June 2022. Three-tiered HER2 status was pathologically determined. Radiologists assessed the conventional MRI features of tumors and manually segmented the tumors on multiparametric sequences (T2-weighted images, DWI, ADC maps, and T1-weighted delayed contrast-enhanced images) to extract radiomics features. Least absolute shrinkage and selection operator analysis was used to develop two radiomics signatures, to differentiate HER2-zero cancers from HER2-low or HER2-positive cancers (task 1) as well as to differentiate HER2-low cancers from HER2-positive cancers (task 2). Patients from hospital 1 were randomly assigned to a discovery set (task 1: n = 376; task 2: n = 335) or an internal validation set (task 1: n = 161; task 2: n = 143); patients from hospital 2 formed an external validation set (task 1: n = 55; task 2: n = 50). Multivariable logistic regression analysis was used to create nomograms combining radiomics signatures with clinicopathologic and conventional MRI features. RESULTS. AUC, sensitivity, and specificity in the discovery, internal validation, and external validation sets were as follows: for task 1, 0.89, 99.4%, and 69.0%; 0.86, 98.6%, and 76.5%; and 0.78, 100.0%, and 0.0%, respectively; for task 2, 0.77, 93.8%, and 32.3%; 0.75, 92.9%, and 6.8%; and 0.77, 97.0%, and 29.4%, respectively. For task 1, no nomogram was created because no clinicopathologic or conventional MRI feature was associated with HER2 status independent of the MRI radiomics signature. For task 2, a nomogram including an MRI radiomics signature and three pathologic features (histologic grade of III, high Ki-67 index, and positive progesterone receptor status) that were independently associated with HER2-low expression had an AUC of 0.87, 0.83, and 0.80 in the three sets. CONCLUSION. MRI radiomics features were used to differentiate HER2-zero from HER2-low cancers or HER2-positives cancers as well as to differentiate HER2-low cancers from HER2-positive cancers. CLINICAL IMPACT. MRI radiomics may help select patients for novel or traditional HER2-targeted therapies, particularly those patients with ambiguous results of immunohistochemical staining results or limited access to fluorescence in situ hybridization.
引用
- Peng Y, Zhang X, Qiu Y, et al. Development and Validation of MRI Radiomics Models to Differentiate HER2-Zero, -Low, and -Positive Breast Cancer. AJR Am J Roentgenol. 2024. PMID: 38265001. doi:10.2214/AJR.23.30603
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。